<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Neurodegener</journal-id>
<journal-title-group>
<journal-title>Molecular Neurodegeneration</journal-title>
</journal-title-group>
<issn pub-type="epub">1750-1326</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27400746</article-id>
<article-id pub-id-type="pmc">4940708</article-id>
<article-id pub-id-type="publisher-id">119</article-id>
<article-id pub-id-type="doi">10.1186/s13024-016-0119-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kazim</surname>
<given-names>Syed Faraz</given-names>
</name>
<address>
<email>Faraz.Syed@downstate.edu</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Iqbal</surname>
<given-names>Khalid</given-names>
</name>
<address>
<phone>1-718 494-5259</phone>
<email>khalid.iqbal.ibr@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><label></label>Department of Neurochemistry, and SUNY Downstate/NYSIBR Program in Developmental Neuroscience, New York State Institute for Basic Research (NYSIBR), 1050 Forest Hill Road, Staten Island, NY 10314 USA </aff>
<aff id="Aff2"><label></label>Graduate Program in Neural and Behavioral Science, and Department of Physiology and Pharmacology, State University of New York (SUNY) Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>11</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<elocation-id>50</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Alzheimer’s disease (AD) is an incurable and debilitating chronic progressive neurodegenerative disorder which is the leading cause of dementia worldwide. AD is a heterogeneous and multifactorial disorder, histopathologically characterized by the presence of amyloid β (Aβ) plaques and neurofibrillary tangles composed of Aβ peptides and abnormally hyperphosphorylated tau protein, respectively. Independent of the various etiopathogenic mechanisms, neurodegeneration is a final common outcome of AD neuropathology. Synaptic loss is a better correlate of cognitive impairment in AD than Aβ or tau pathologies. Thus a highly promising therapeutic strategy for AD is to shift the balance from neurodegeneration to neuroregeneration and synaptic repair. Neurotrophic factors, by virtue of their neurogenic and neurotrophic activities, have potential for the treatment of AD. However, the clinical therapeutic usage of recombinant neurotrophic factors is limited because of the insurmountable hurdles of unfavorable pharmacokinetic properties, poor blood–brain barrier (BBB) permeability, and severe adverse effects. Neurotrophic factor small-molecule mimetics, in this context, represent a potential strategy to overcome these short comings, and have shown promise in preclinical studies. Neurotrophic factor small-molecule mimetics have been the focus of intense research in recent years for AD drug development. Here, we review the relevant literature regarding the therapeutic beneficial effect of neurotrophic factors in AD, and then discuss the recent status of research regarding the neurotrophic factor small-molecule mimetics as therapeutic candidates for AD. Lastly, we summarize the preclinical studies with a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic, Peptide 021 (P021). P021 is a neurogenic and neurotrophic compound which enhances dentate gyrus neurogenesis and memory processes via inhibiting leukemia inhibitory factor (LIF) signaling pathway and increasing brain-derived neurotrophic factor (BDNF) expression. It robustly inhibits tau abnormal hyperphosphorylation via increased BDNF mediated decrease in glycogen synthase kinase-3β (GSK-3β, major tau kinase) activity. P021 is a small molecular weight, BBB permeable compound with suitable pharmacokinetics for oral administration, and without adverse effects associated with native CNTF or BDNF molecule. P021 has shown beneficial therapeutic effect in several preclinical studies and has emerged as a highly promising compound for AD drug development.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Alzheimer’s disease</kwd>
<kwd>Cognition</kwd>
<kwd>Neurotrophic factor small-molecule mimetics</kwd>
<kwd>Brain-derived neurotrophic factor (BDNF)</kwd>
<kwd>Ciliary neurotrophic factor (CNTF)</kwd>
<kwd>Amyloid beta</kwd>
<kwd>Tau</kwd>
<kwd>Neurogenesis</kwd>
<kwd>Synaptic loss</kwd>
<kwd>Neurodegeneration</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id>
<institution>Alzheimer's Association</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002565</institution-id>
<institution>Alzheimer's Drug Discovery Foundation</institution>
</institution-wrap>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>EVER NeuroPharma GmbH, Unterach, Austria</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>Doctoral fellowship from SUNY Downstate/NYSIBR Program in Developmental Neuroscience</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Background</title>
<p>Alzheimer’s disease (AD) is a chronic, debilitating, neurodegenerative disorder and is the most common form of dementia in the elderly [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. AD is the sixth leading cause of mortality in the United States, and affects nearly 5.4 million Americans [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Approximately 476,000 people age 65 or older are expected to develop AD in the United States in the year 2016, and the total healthcare expenditure for AD and related dementias will be nearly 236 billion dollars, making it one of the costliest chronic diseases in the United States [<xref ref-type="bibr" rid="CR4">4</xref>]. Worldwide, AD and related dementias affect approximately 47 million people [<xref ref-type="bibr" rid="CR5">5</xref>]. As yet there is no effective cure for AD [<xref ref-type="bibr" rid="CR6">6</xref>]. By the year 2050, the prevalence of AD is projected to be 13.8 million in United States [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], and 135 million worldwide [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], lest an effective AD therapy is developed.</p>
<p>AD is clinically characterized by a heterogeneous set of symptoms including progressive memory impairment, visuospatial decline, aphasia, and loss of executive function [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Short-term memory loss is the most common early symptom of AD [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Histopathologically, there are two major lesions in AD: senile plaques (diffuse and neuritic) and neurofibrillary tangles (NFTs) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Amyloid β (Aβ) is the main component of the senile plaques whereas abnormally hyperphosphorylated tau protein gives rise to NFTs [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Alongside Aβ plaques and NFTs, impairments in adult hippocampal neurogenesis and synaptic plasticity, synaptic deficit, and profound neurodegeneration are also major features of AD [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. Adult hippocampal neurogenesis and synaptic plasticity have been proposed to be essential for learning and memory [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. Alterations in adult hippocampal neurogenesis and synaptic plasticity could thus be the major mechanisms underlying cognitive dysfunction in AD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. AD has also been characterized as a consequence of synaptic failure [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Several studies have shown that synaptic loss correlates better with cognitive decline than either Aβ plaque load or NFTs [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. Targeting the impairment in adult hippocampal neurogenesis and neuronal and synaptic loss has been proposed as a potential therapeutic approach to rescue cognitive dysfunction in AD [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p>
</sec>
<sec id="Sec2">
<title>Main text</title>
<sec id="Sec3">
<title>Etiopathogenesis of Alzheimer’s disease</title>
<p>AD, first described by German psychiatrist Alois Alzheimer in 1907 [<xref ref-type="bibr" rid="CR37">37</xref>], is a multifactorial and heterogeneous disease, and apparently involves several different etiopathogenic mechanisms (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. The early-onset familial form of AD which is caused by mutations in amyloid β precursor protein (APP), presenilin 1 (PS1), or presenilin 2 (PS2), accounts for &lt;1 % of all cases (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) (for review, [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]). The exact causes of the late-onset sporadic form of AD, which accounts for over 99 % of the cases, are not yet understood. The sporadic form of AD probably involves several different etiopathogenic mechanisms in concert with aging such as metabolic derangements, head trauma, metal ion toxicity, hypertension, vascular injury, smoking, psychological stress, and vitamin deficiencies (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) [<xref ref-type="bibr" rid="CR38">38</xref>]. No known mutations are involved in sporadic form of AD, however, the presence of one or two apolipoprotein E epsilon 4 (APOE ε4) alleles increases the disease risk ~3.5-fold or ~10-fold, respectively [<xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Multifactorial nature of AD and involvement of several different etiopathogenic mechanisms. Early-onset familial AD caused by mutations in APP, PS1, or PS2 constitutes &lt; 1 % of AD cases. The exact causes of late-onset sporadic AD which accounts for the remaining &gt; 99 % of AD cases are as yet largely unknown. However, aging alongside gene-environment interaction is speculated to contribute to this form of AD. Both forms of AD lead to amyloid plaque and neurofibrillary pathologies, synaptic dysfunction and neurodegeneration, and ultimately cognitive impairment</p></caption><graphic id="MO1" xlink:href="13024_2016_119_Fig1_HTML"></graphic></fig></p>
<p>The histopathological hallmarks in both the sporadic and the familial forms of AD are similar and include amyloid β plaques and NFTs leading to neurodegeneration (Fig. <xref ref-type="fig" rid="Fig2">2</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>]. The immensely popular amyloid cascade hypothesis suggests a major etiological role of Aβ for the NFT pathology, neurodegeneration and cognitive dysfunction in AD [<xref ref-type="bibr" rid="CR42">42</xref>]. Aβ plaques are produced by amyloidogenic processing of the transmembrane protein, APP, by β- and γ-secretase enzymes resulting in the formation of major toxic products, Aβ40 and Aβ42 peptides (Fig. <xref ref-type="fig" rid="Fig2">2</xref>) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The oligomeric form of Aβ has also been suggested as the main neurotoxic state of the peptide [<xref ref-type="bibr" rid="CR45">45</xref>]. Aβ oligomers are known to inhibit hippocampal long-term potentiation (LTP) [<xref ref-type="bibr" rid="CR46">46</xref>], a major cellular mechanism underlying synaptic plasticity, and learning and memory [<xref ref-type="bibr" rid="CR47">47</xref>]. Amyloid cascade hypothesis also derives its major support from the Down syndrome individuals; as part of the trisomy 21, these patients carry 3 copies of APP and almost all of them develop AD neuropathological characteristics by the age of 40 years [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Aβ plaques and NFTs as hallmarks of AD. AD is characterized by extracellular deposits of Aβ (senile) plaques and intraneuronal NFTs leading to neurodegeneration, and ultimately cognitive impairment and dementia. Aβ plaques are produced by the amyloidogenic processing of APP by β- and γ-secretase enzymes leading to the formation of Aβ peptides (36–43 amino acids) of which the Aβ40 and Aβ42 are the most common. Aβ42 is the most fibrillogenic and thus most amyloidogenic Aβ peptide. Aβ oligomers impair hippocampal LTP, and thus synaptic plasticity, and learning and memory. NFTs are intracellular aggregates of MAP-tau which is abnormally hyperphosphorylated by upregulation of activities of kinases such as GSK3β and Cdk5 or deficit in phosphatases such as PP2A</p></caption><graphic id="MO2" xlink:href="13024_2016_119_Fig2_HTML"></graphic></fig></p>
<p>Tau which is a neuronal microtubule associated protein (MAP) is a major protein subunit of paired helical filaments that constitute the NFTs (Fig. <xref ref-type="fig" rid="Fig2">2</xref>) [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Tau in NFTs is abnormally hyperphosphorylated [<xref ref-type="bibr" rid="CR13">13</xref>]. Tau is a substrate for several protein kinases including cyclin-dependent kinase 5 (Cdk5), glycogen synthase kinase 3 β (GSK-3β), and calcium/calmodulin activated protein kinase II (CaMKII) [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. The activities of several major tau kinases are regulated by protein phosphatase 2A (PP2A). PP2A can thus regulate the tau phosphorylaiton both directly and by inhibiting the activities of tau protein kinases [<xref ref-type="bibr" rid="CR54">54</xref>]. PP2A activity is impaired and is possibly a cause of the abnormal hyperphosphorylation of tau in AD brain [<xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref>].</p>
</sec>
<sec id="Sec4">
<title>Stages of Alzheimer’s disease</title>
<p>The neuropathologic staging of AD is performed based on three parameters (Aβ, Braak, and Consortium to Establish a Registry for AD, CERAD) to obtain an “ABC” score: histopathologic assessments of Aβ-containing amyloid plaques (A), Braak staging of NFTs (B), and scoring of neuritic amyloid plaques (C). The NFT load in AD brain are known to correlate better with cognitive decline [<xref ref-type="bibr" rid="CR58">58</xref>]. In the earliest stages of AD (Braak stage I-II, prodromal AD), NFTs are confined to the entorhinal cortex [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Subsequently, NFTs spread to the limbic and medial temporal lobe (Braak stage III-IV; mild cognitive impairment, MCI, or early AD); this stage correlates with early memory related symptoms in AD [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. During the late stages (Braak stage V–VI, clinical AD), the number of NFTs increase and they occur in neocortical areas leading to impairments in higher cognitive functions such as executive and visuospatial abilities, and speech in concert with AD-related cognitive deficits [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
<p>AD is a progressive neurodegenerative disorder (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). As mentioned before, the earliest neuropathological changes in AD are in the hippocampus and entorhinal cortex, followed by changes in the medial temporal lobe [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR68">68</xref>]. Correspondingly, the earliest detectable cognitive deficit is in the medial temporal lobe dependent episodic memory [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Episodic memory deficits are followed by impairment in semantic memory; both memory domains depend on the neural circuitry of medial and lateral temporal lobes and occur prior to deficit in higher cognitive functions such as attention, and executive and visuospatial capabilities [<xref ref-type="bibr" rid="CR71">71</xref>]. Mild deficits in executive functioning are first detectable near the end of the preclinical phase of AD [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. As the patient progresses from preclinical stage of AD into MCI, more cognitive functions begin to be impaired including verbal recall and deterioration of general memory domain [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. As the patient progresses from MCI into mild, moderate, and subsequently the severe stages of AD, general cognition continues to decline with impairment manifesting in all cognitive domains [<xref ref-type="bibr" rid="CR75">75</xref>].<fig id="Fig3"><label>Fig. 3</label><caption><p>Progression of neuropathology and cognitive impairment in AD. The earliest AD neuropathology develops in medial temporal lobe and gives rise to episodic memory deficit followed by impairment in semantic memory (preclinical AD). As the patient progresses to MCI stage, higher cognitive domains such as attention, executive function, visuospatial memory, and verbal recall become impaired. Also, general cognition starts to decline. As the patient progresses to mild to moderate AD stages, the neuropathology spreads to frontal and parietal lobes, and all cognitive domains become affected. In severe stage of AD, the neuropathology spreads to involve all brain lobes, and a profound deficit in all cognitive domains is noted</p></caption><graphic id="MO3" xlink:href="13024_2016_119_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec5">
<title>Neurogenic and synaptic failure in Alzheimer’s disease</title>
<p>Adult hippocampal neurogenesis plays a pivotal role in learning and memory [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. The essential role of adult-born hippocampal neurons has been suggested in complex forms of spatial and associative memory [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR77">77</xref>–<xref ref-type="bibr" rid="CR81">81</xref>]. In rodents, the aberrant hippocampal neurogenesis leads to impairment in different forms of hippocampus dependent learning such as in Morris water maze and contextual fear conditioning tasks [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. AD and other neurodegenerative diseases are characterized by an imbalance between neurogenesis and neurodegeneration [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Consequently, the impairment in neurogenesis has been hypothesized to contribute to learning and memory deficits in AD [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR84">84</xref>].</p>
<p>In adult hippocampus, the survival, maturation, and integration of new born neurons in the dentate gyrus depends on the appropriate <italic>brain milieu</italic> or microenvironment primarily provided by the neurotrophic factors [<xref ref-type="bibr" rid="CR85">85</xref>–<xref ref-type="bibr" rid="CR89">89</xref>]. The dentate gyrus microenvironment in neurodegenerative conditions such as AD is not conducive for the neurogenesis and the survival, maturation, and integration of new born neurons into the hippocampal functional circuitry [<xref ref-type="bibr" rid="CR90">90</xref>–<xref ref-type="bibr" rid="CR92">92</xref>]. The AD brain responds to neurodegeneration by stimulating neurogenesis, however, because of the lack of a proper neurotrophic microenvironment of the hippocampus, this effort of the AD brain to replace lost neurons with new neurons is unsuccessful and culminates in failure of neuronal survival, maturation, and integration [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. As the disease progresses, the neurogenic failure becomes severe, and contributes significantly to cognitive decline [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p>
<p>AD has been described as a synaptic failure [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. AD brains also show dendritic and dendritic spine loss [<xref ref-type="bibr" rid="CR94">94</xref>]. Quantitative studies on AD brains within 2–4 years after the clinically diagnosed disease showed a 25–35 % decrease in synaptic density and a 15–35 % synaptic loss per neuron in the frontal and temporal lobes of the cerebral cortex [<xref ref-type="bibr" rid="CR15">15</xref>]. The extent of synaptic loss is even more severe in the hippocampus where it amounts to 44–55 % [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Remarkably, the synaptic loss in frontal cortex and limbic system is the best correlate of the severity of cognitive dysfunction [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>]. The profound neuronal, synaptic, and dendritic loss may contribute to impaired synaptic plasticity, including reduced LTP, in AD. Synaptic plasticity is known to be the cellular substrate of learning and memory [<xref ref-type="bibr" rid="CR29">29</xref>]. Additionally, adult hippocampal neurogenesis has been proposed to play a pivotal role in synaptic plasticity, and subsequently, learning and memory processes in the hippocampus [<xref ref-type="bibr" rid="CR97">97</xref>]. Both human AD cases and AD transgenic mice exhibit significant alterations in the process of adult hippocampal neurogenesis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR98">98</xref>–<xref ref-type="bibr" rid="CR104">104</xref>]. The synaptic plasticity impairments in AD, thus, may not only be the consequence of synaptic failure but also impaired neurogenesis.</p>
</sec>
<sec id="Sec6">
<title>Shifting the balance from neurodegeneration to neural regeneration to treat Alzheimer’s disease</title>
<p>The final common outcome of various different etiopathogenic mechanisms involved in AD is neurodegeneration leading to cognitive impairment. Thus, a highly promising therapeutic strategy for AD is to shift the balance from neurodegeneration to neural regeneration [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. This can be achieved by utilizing means that can enhance adult hippocampal neurogenesis and neuronal and synaptic plasticity. Several different approaches have been employed in rodent models of AD with reasonable success to enhance neurogenesis and neuronal and synaptic plasticity [<xref ref-type="bibr" rid="CR105">105</xref>]. Neural stem cells-based replacement approach for AD is currently the focus of intense research and has shown promising results in animal models of AD [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Neural stem cell implantation in the triple transgenic AD mice (3xTg-AD) that harbor mutated human APP, tau, and PS1, has been reported to rescue cognitive impairment via increased brain derived neurotrophic factor (BDNF) expression [<xref ref-type="bibr" rid="CR108">108</xref>]. Pharmacological stimulation of neural stem cells with neurotrophic factors and growth factors such as fibroblast growth factor 2 (FGF2) [<xref ref-type="bibr" rid="CR109">109</xref>], BDNF [<xref ref-type="bibr" rid="CR110">110</xref>], ciliary neurotrophic factor (CNTF) [<xref ref-type="bibr" rid="CR111">111</xref>] has also shown promise in mouse models of AD.</p>
</sec>
<sec id="Sec7">
<title>Neurotrophic factors --- potent neuronal and synaptic repair molecules for the treatment of Alzheimer’s disease</title>
<p>Neurotrophic factors can be broadly divided into 3 families: (1) neurotrophins, (2) glial cell-line derived neurotrophic factor (GDNF) family ligands (GFLs), and (3) neuropoeitic cytokines [<xref ref-type="bibr" rid="CR112">112</xref>]. The neuroprotective effect of various neurotrophic factors via neuroregeneration and synaptic repair is well established [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>].</p>
<p>The neurotrophin family comprises nerve growth factor (NGF), BDNF, neurotrophin 3 (NT3), and neurotrophin 4 (NT4) [<xref ref-type="bibr" rid="CR115">115</xref>]. Neurotrophin signaling is mediated via two receptor types: p75 neurotrophin receptor (p75<sup>NTR</sup>) and tropomysin receptor kinase (Trk) [<xref ref-type="bibr" rid="CR115">115</xref>]. Each Trk receptor selectively binds to different neurotrophins: NGF binds to TrkA, BDNF and NT4 bind to TrkB, and NT3 binds to TrkC [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Neurotrophin signaling occurs via several different pathways including two major tyrosine kinase-mediated pathways: the phosphoinositide 3-kinase (PI3K)-AKT (also known as protein kinase B, PKB) pathway and the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) pathway [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. The neurotrophin signaling mediates neuronal survival, proliferation, and differentiation [<xref ref-type="bibr" rid="CR115">115</xref>]. Imbalance in the neurotrophin levels in different brain regions has been shown in AD cases [<xref ref-type="bibr" rid="CR116">116</xref>]. BDNF levels have been shown to be decreased in AD brains suggesting a lack of trophic support that may contribute significantly to neurodegeneration [<xref ref-type="bibr" rid="CR116">116</xref>–<xref ref-type="bibr" rid="CR119">119</xref>]. BDNF is essential for basal level of adult hippocampal neurogenesis and also for the survival and integration of new-born neurons into the hippocampal circuitry [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. BDNF also plays a crucial role in both the early and late phases of LTP, the cellular substrate for learning and memory [<xref ref-type="bibr" rid="CR122">122</xref>–<xref ref-type="bibr" rid="CR125">125</xref>]. In mouse and primate models of AD, entorhinal cortex administration of BDNF was found to have a beneficial effect on cognition [<xref ref-type="bibr" rid="CR110">110</xref>]. In human AD cases, decreased NGF levels have been shown in the nucleus basalis of Meynert [<xref ref-type="bibr" rid="CR126">126</xref>], a group of neurons in the basal forebrain which has wide ascending projections to the neocortex, is rich in acetylcholine (Ach) and choline acetyltransferase (ChAT), and is well known to undergo degeneration in AD [<xref ref-type="bibr" rid="CR127">127</xref>]. In animal models, it has been demonstrated that the ascending cholinergic projections in the brain express low- and high-affinity NGF receptors and are NGF-sensitive and probably NGF-dependent [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. Cholinergic degeneration leads to cognitive dysfunction, and treatment with NGF can improve cognition in animal models [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. NGF gene therapy has recently been shown to exert a neurotrophic effect in AD patients [<xref ref-type="bibr" rid="CR130">130</xref>].</p>
<p>The GDNF family of ligands (GFL) comprises of four neurotrophic factors: GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN) [<xref ref-type="bibr" rid="CR131">131</xref>]. GFL signaling occurs through binding of a particular GFL dimer to a cell surface bound co-receptor, a member of the GFRα protein family, and subsequent activation of a receptor tyrosine kinase molecule, RET (“rearranged during transfection”) [<xref ref-type="bibr" rid="CR131">131</xref>]. The primary ligands for the co-receptors GFRα1, GFRα2, GFRα3, and GFRα4 are GDNF, NRTN, ARTN, and PSPN, respectively [<xref ref-type="bibr" rid="CR131">131</xref>]. GFLs play a role in several different processes including neuronal survival, differentiation, and migration, and neurite outgrowth [<xref ref-type="bibr" rid="CR131">131</xref>]. Deficiency of GFRα1, the receptor for GDNF, have been shown in human AD brains [<xref ref-type="bibr" rid="CR132">132</xref>]. Also, GDNF gene therapy has been reported to protect against AD-like neuropathology in 3xTg-AD mice [<xref ref-type="bibr" rid="CR133">133</xref>].</p>
<p>Neuropoietic cytokines family of neurotrophic factors exert many similar effects including enhancing neuronal proliferation and differentiation, however, this group signals through cytokine receptors rather than receptor tyrosine kinases [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. The transforming growth factor β (TGFβ) and interleukin-6 (IL-6) superfamilies are some of the most abundant and influential neuropoeitic cytokines in the brain, particularly during development [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. The TGFβ superfamily includes brain morphogenic proteins (BMPs) which play a key role in regulating neuron induction [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. BMPs interact with key neurogenic elements including Wnts and sonic hedgehog, and establish cell-fate determination and subtype differentiation [<xref ref-type="bibr" rid="CR136">136</xref>–<xref ref-type="bibr" rid="CR138">138</xref>]. The IL-6 family of cytokines includes CNTF, interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin-M, cardiotrophin-1, and cardiotrophin-like cytokine [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. CNTF plays a pivotal role in adult hippocampal and subventricular zone neurogenesis, and the differentiation of neural stem cells [<xref ref-type="bibr" rid="CR141">141</xref>–<xref ref-type="bibr" rid="CR143">143</xref>]. CNTF signaling occurs through a tripartite complex of CNTF receptor α (CNTFRα), LIF β receptor (LIFR), and glycoprotein 130 (gp130). CNTF and LIF both signal through tyrosine phosphorylation (Tyr706) of the signal transducers and activators of transcription (STAT) proteins by the membrane associated Janus kinase (JAK) [<xref ref-type="bibr" rid="CR144">144</xref>]. In the brain, CNTF is expressed in astrocytes in the neurogenic niches [<xref ref-type="bibr" rid="CR145">145</xref>], while its receptor, CNTFRα, is expressed predominantly in neural progenitor cells and hippocampal neurons, and various other areas of the brain including motor cortex and cerebellum [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]. Overall, CNTF is the most extensively studied neuropoetic cytokine, and its neuroprotective effects are well established [<xref ref-type="bibr" rid="CR146">146</xref>]. CNTF administration has been shown to alleviate cognitive impairment and to stabilize synaptic protein levels in a transgenic mouse model of AD [<xref ref-type="bibr" rid="CR111">111</xref>].</p>
</sec>
<sec id="Sec8">
<title>Neurotrophic factor small-molecule mimetics for the treatment of Alzheimer’s disease</title>
<p>The therapeutic usage of neurotrophic factors such as BDNF and CNTF in AD patients is hindered by limited blood–brain barrier (BBB) permeability, poor plasma stability and unsuitable pharmacokinetics, and unwanted systemic effects [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR147">147</xref>–<xref ref-type="bibr" rid="CR149">149</xref>]. The recombinant BDNF or CNTF in clinical trials have shown limited bioavailability and multiple adverse effects [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. A promising strategy to bypass these limitations to develop neurotrophic factors based drugs for AD which has emerged during the last decade or so is to develop small-molecule mimetics that could exert the therapeutic beneficial effects of neurotrophic factors on neurogenesis, neuronal and synaptic plasticity, and ultimately cognition, with suitable pharmacokinetics and central nervous system (CNS) penetration for drug development, and without unwanted systemic effects produced by the full-length native molecules [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR152">152</xref>–<xref ref-type="bibr" rid="CR156">156</xref>]. A major problem associated with the therapeutic usage of whole molecule neurotrophic factors is the pleiotropic actions that derive from their concomitant binding to multiple receptors [<xref ref-type="bibr" rid="CR154">154</xref>]. The small-molecule mimetics might also allow to modulate various aspects of these signaling pathways in ways that are distinct from the whole molecule neurotrophic factors [<xref ref-type="bibr" rid="CR154">154</xref>]. By departing from conventional neurotrophic factor signaling, these small-molecule mimetics might provide a novel therapeutic approach to treat AD [<xref ref-type="bibr" rid="CR154">154</xref>].</p>
<p>Early attempts to develop small-molecule mimetics of neurotrophic factors focused on synthesizing peptidergic compounds consisting of amino acids residues corresponding to various NGF domains [<xref ref-type="bibr" rid="CR154">154</xref>]. The first small peptide molecule corresponding to an NGF domain demonstrated to exert a neurotrophic effect was the cyclized dimeric form of peptide P7 (amino acid residues, KGKE) which acted through p75<sup>NTR</sup> receptor [<xref ref-type="bibr" rid="CR157">157</xref>]. The NGF small peptide mimetics containing KGKE or a homologous sequence have been reported to block Aβ binding to p75<sup>NTR</sup> and protect against Aβ-induced cell death [<xref ref-type="bibr" rid="CR158">158</xref>]. Another NGF small peptide mimetic, compound D3, which corresponds to amino acid side chains of NGF β-turn loops and acts through TrkA receptor, has been shown to rescue basal forebrain cholinergic neurodegeneration and spatial reference memory in aged rats [<xref ref-type="bibr" rid="CR159">159</xref>]. Also, the administration of compound D3 via intracerebroventricular mini pump in J20 mice, which carry APP Swedish and Indiana mutations, has been shown to rescue learning and short-term memory deficits [<xref ref-type="bibr" rid="CR160">160</xref>].</p>
<p>Small-molecule modulation of BDNF receptor, TrkB, for the treatment of neurodegenerative disorders including AD, has been the focus of intense research in recent years [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. A naturally occurring flavone, 7,8-dihydroxyflavone (7,8-DHF), which can induce the phosphorylation of TrkB and its downstream mediators, AKT and ERK, has been shown to be neuroprotective and neurotrophic [<xref ref-type="bibr" rid="CR161">161</xref>–<xref ref-type="bibr" rid="CR163">163</xref>]. In studies employing transgenic mouse models of AD, 7,8-DHF has shown beneficial effect on learning and memory [<xref ref-type="bibr" rid="CR164">164</xref>–<xref ref-type="bibr" rid="CR166">166</xref>]. R7, a prodrug of 7,8-DHF, with considerably improved potency and favorable pharmacokinetics, is currently in preclinical development for the treatment of AD [<xref ref-type="bibr" rid="CR167">167</xref>]. A BDNF small-molecule mimetic compound, LM22A-4, identified using <italic>in silico</italic> screening with a BDNF loop-domain pharmacophore, was found to promote survival of hippocampal neurons (~85 % of the efficacy of BDNF), induce TrkB phosphorylation, and prevent neuronal death in an in vitro model of AD [<xref ref-type="bibr" rid="CR168">168</xref>]. Other TrkB small molecule mimetics that have shown promise in preclinical studies include de-oxygedunin [<xref ref-type="bibr" rid="CR169">169</xref>], N-acetylserotonin [<xref ref-type="bibr" rid="CR170">170</xref>], adenosine 2A receptor agonist [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>], and BDNF loop mimetics [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. Recently, our lab also identified BDNF tetrapeptides (peptide B1-B5) which can modulate TrkB signaling and exert neurotrophic effect in mouse hippocampal primary neuronal cultures [<xref ref-type="bibr" rid="CR175">175</xref>].</p>
<p>A p75<sup>NTR</sup> small-molecule non-peptide mimetic identified through <italic>in silico</italic> screening, LM11A-31, also known as C31, is a highly promising AD drug candidate [<xref ref-type="bibr" rid="CR154">154</xref>]. LM11A-31 has been shown to block Aβ-induced deleterious signaling, including the activation of calpain-Cdk5, GSK-3β, and c-jun N-terminal kinase (JNK) signaling, and reduce Aβ-induced tau hyperphosphorylation and the inactivation of AKT and cAMP-response element-binding protein (CREB) [<xref ref-type="bibr" rid="CR176">176</xref>]. LM11A-31 has also been reported to exert beneficial effect both at early and late stages of the AD-like neuropathology in transgenic mice [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]. LM11A-31, has successfully completed a Phase I clinical trial without any significant adverse effects, and is currently undergoing Phase IIa clinical trial in human AD patients.</p>
<p>Neurotrophic factor small-molecule mimetics offer several advantages as compared to native neurotrophic factor molecules including suitable pharmacokinetics and enhanced BBB permeability for drug development. However, there are certain limitations such as insufficient receptor specificity, requirement for continuous dosing, and effects which are not brain region-specific [<xref ref-type="bibr" rid="CR154">154</xref>]. These limitations need to be taken into consideration for neurotrophic factor small-molecule mimetics based drugs [<xref ref-type="bibr" rid="CR154">154</xref>].</p>
</sec>
<sec id="Sec9">
<title>CNTF small-molecule peptide mimetic, P021, as a drug candidate for Alzheimer’s disease</title>
<p>As mentioned before, the neuroprotective effects of CNTF are well established [<xref ref-type="bibr" rid="CR146">146</xref>], and it has been reported to rescue cognitive dysfunction in AD transgenic mice [<xref ref-type="bibr" rid="CR111">111</xref>]. However, like other neurotrophic factors, the clinical therapeutic usage of CNTF is restricted due to its short plasma half-life and severe adverse effects including anorexia, skeletal muscle loss, muscle pain and cramps, and hyperalgesia, experienced upon peripheral administration in humans [<xref ref-type="bibr" rid="CR150">150</xref>].</p>
<p>Our laboratory generated an 11-mer CNTF small-molecule peptide mimetic, Peptide 6 (P6; Ac-VGDGGLFEKKL-NH<sub>2</sub>), which corresponds to a biologically active region (amino acid residues 146–156) of human CNTF and was identified using epitope mapping and employing neutralizing antibodies (Fig. <xref ref-type="fig" rid="Fig4">4</xref>) [<xref ref-type="bibr" rid="CR179">179</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. P6 has a plasma half-life of over 6 h as compared to ~ 3 min plasma half-life of recombinant CNTF, and is BBB permeable [<xref ref-type="bibr" rid="CR180">180</xref>]. P6 acts by competitively inhibiting the LIF signaling, thus promoting the formation of neural precursor cells (NPCs), and by increasing BDNF mRNA levels, thus increasing the survival, maturation, and integration of new-born cells (Fig. <xref ref-type="fig" rid="Fig4">4</xref>) [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. Peripheral administration of P6 for 30 days via a subcutaneously implanted slow release bolus, was found to enhance dentate gyrus neurogenesis, neuronal plasticity, and spatial memory of the normal adult C57Bl/6 mice [<xref ref-type="bibr" rid="CR180">180</xref>]. The intraperitoneal administration of P6 for six weeks in 6–7 month-old 3xTg-AD mice (at early stages of the AD pathology prior to Aβ plaques and neurofibrillary tangle-like pathology) ameliorated impairment in spatial reference memory and short-term episodic memory by enhancing dentate gyrus neurogenesis and neuronal plasticity in these mice [<xref ref-type="bibr" rid="CR98">98</xref>]. The 3xTg-AD mice carry AD-related mutation including human PS1 M146V, human APP Swedish, and human tau P301L [<xref ref-type="bibr" rid="CR182">182</xref>], and develop Aβ plaques and neurofibrillary tangle-like pathologies in a progressive and age-dependent manner, starting at ~9 and ~12 months respectively but show cognitive impairment as early as 3–5 months of age [<xref ref-type="bibr" rid="CR182">182</xref>–<xref ref-type="bibr" rid="CR185">185</xref>]. P6 treatment in 6–7 month-old 3xTg-AD mice could not exert any effect on Aβ and tau pathologies [<xref ref-type="bibr" rid="CR98">98</xref>], seen in this age mice as intraneuronal Aβ accumulation and tau hyperphosphorylation, and not as plaques and tangles [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR183">183</xref>]. Other preclinical studies employing P6 showed neurogenic and neurotrophic effects in animal models of sporadic AD [<xref ref-type="bibr" rid="CR181">181</xref>], familial AD [<xref ref-type="bibr" rid="CR186">186</xref>], Down syndrome [<xref ref-type="bibr" rid="CR187">187</xref>], autism [<xref ref-type="bibr" rid="CR188">188</xref>], and traumatic brain injury [<xref ref-type="bibr" rid="CR189">189</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Design and structures of CNTF small-molecule mimetics and their mechanism of action to enhance formation of NPCs and mature neurons. <bold>a</bold> Protein Data Base rendering of one 4-helix bundle of truncated human CNTF (Residues 2–187), generated from CNTF. Only one protein chain is shown for clarity. Residues 149GGLFEKKL156 are shown as a tube model, while the rest of the sequence are presented as ribbon [<xref ref-type="bibr" rid="CR98">98</xref>]. The structures of P6 and P021 are also shown. From the neurogenic 11-mer, Ac-VGDGGLFEKKL-NH<sub>2</sub> (P6), a truncated, still neurogenic pentamer, with an adamantylated glycine group (red oval), Ac-DGGLA<sup>G</sup>-NH<sub>2</sub> (P021) was designed [<xref ref-type="bibr" rid="CR191">191</xref>]. <bold>b</bold> P6 and P021 enhance neural progenitor cells (NPCs) formation and maturation and integration of new-born neurons by competitively inhibiting the LIF signaling and increasing BDNF expression respectively [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>, <xref ref-type="bibr" rid="CR191">191</xref>, <xref ref-type="bibr" rid="CR192">192</xref>]</p></caption><graphic id="MO4" xlink:href="13024_2016_119_Fig4_HTML"></graphic></fig></p>
<p>To increase the “drug-like” pharmacokinetic properties, we narrowed down the minimal active region of P6 to 4 amino acid residues (Ac-DGGL-NH<sub>2</sub>, Peptide 6c, P6c) which could still exert neurogenic and neurotrophic effects [<xref ref-type="bibr" rid="CR190">190</xref>]. We subsequently added adamantylated glycine group to P6c to enhance its BBB permeability, and the resultant pentamer (Ac-DGGL<sup>A</sup>G-NH<sub>2</sub>), called Peptide 021 (P021) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>), was found to enhance proliferation and differentiation of adult hippocampal progenitors, increase synaptic markers expression, and improve cognition in C57Bl/6 mice [<xref ref-type="bibr" rid="CR191">191</xref>]. Oral administration of the compound P021 could rescue cognitive aging by enhancing neurogenesis via increased BDNF expression and by decreasing tau levels in aged Fisher rats [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>].</p>
<p>In a recent study, we treated 3xTg-AD mice with P021 in diet (60 nmol/g feed) starting at 9–10 months of age (early-moderate stages of the AD-like neuropathology) for 12 months, and evaluated the therapeutic effect of the compound at 15–16 months of age (moderate-severe pathology) and at 21–22 months of age (severe pathology) [<xref ref-type="bibr" rid="CR99">99</xref>]. P021 treatment significantly reduced tau pathology both at moderate and severe stages of the pathology in 3xTg-AD mice (Fig. <xref ref-type="fig" rid="Fig5">5</xref>), however, the effect of P021 on Aβ pathology was limited to a significant decrease in soluble Aβ levels and a trend towards reduction in Aβ plaque load in CA1 region of hippocampus, consistent with reduction in Aβ generation and not clearance (Fig. <xref ref-type="fig" rid="Fig6">6</xref>) [<xref ref-type="bibr" rid="CR99">99</xref>]. P021 treatment also rescued cognitive impairment, enhanced dentate gyrus neurogenesis, and ameliorated synaptic deficit at moderate to severe stage of the pathology in 3xTg-AD mice (Fig. <xref ref-type="fig" rid="Fig7">7</xref>). The effect of P021 on tau and probably also on Aβ pathology was via increased BDNF expression mediated activation of TrkB-PI3K-AKT signaling pathway which leads to down-stream inhibition of GSK-3β activity by increase in its inhibitory phosphorylation at Ser9 by AKT (Fig. <xref ref-type="fig" rid="Fig8">8</xref>) [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR194">194</xref>]. GSK3β is a major tau serine/threonine kinase which is known to phosphorylate tau at many different sites including Ser199, Ser202, Thr205, Ser396, and Ser404 [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Reduction in GSK3β activity has also been demonstrated to ameliorate Aβ pathology via reduction in amyloidogenic processing of APP [<xref ref-type="bibr" rid="CR195">195</xref>, <xref ref-type="bibr" rid="CR196">196</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>P021 treatment reduces abnormal hyperphosphorylation of tau in 3xTg-AD mice. Reprinted from Kazim et al. [<xref ref-type="bibr" rid="CR99">99</xref>] with permission from Elsevier. <bold>a</bold>-<bold>d</bold> In the subiculum and the CA1 regions of the hippocampus, AT8 (phospho-tau: pSer202, pThr 205) load was significantly reduced by P021 treatment in 3xTg-AD mice (both 15–16 month-old/6 months treatment group and 21–22 month-old/12 months treatment group). <bold>a</bold> Representative photomicrographs illustrating AT8 immunoreactivity in the different regions of hippocampus from the 15–16 month-old/6 months treatment group are shown. <bold>b</bold> The AT8 load was calculated as the percentage of area occupied by immunoreactive label. Quantification of the immunoreactivity is shown as mean ± S.E.M. from Tg-Vh (<italic>n</italic> = 7), and Tg-P021 (<italic>n</italic> = 7). <bold>c</bold> Representative photomicrographs illustrating AT8 immunoreactivity in the different regions of hippocampus from the 21–22 month-old/12 months treatment group are shown. <bold>d</bold> The AT8 load calculated as the percentage of area occupied by immunoreactive label is shown as mean ± S.E.M. from Tg-Vh (<italic>n</italic> = 6), and Tg-P021 (<italic>n</italic> = 6). <bold>e</bold>, <bold>f</bold> Western blot analyses of tau pathology in 21–22 month old (12 months treatment) group. P021 treatment significantly reduced abnormal hyperphosphorylation of tau at sites pSer396/pSer404 (PHF-1) and pSer262/pSer356 (12E8). Pan-tau antibody, R134d did not show any significant difference between groups. Blots developed with human specific tau antibody 43D showed the protein expression only in 3xTg-AD mice. Quantification of the Western blots is shown as mean ± S.E.M. from WT-Vh (<italic>n</italic> = 5), WT-P021 (<italic>n</italic> = 5), Tg-Vh (<italic>n</italic> = 6), and Tg-P021 (<italic>n</italic> = 7). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, and ***<italic>p</italic> &lt; 0.001. <italic>Scale bar</italic> = 100 μm. WT-Vh = wild-type control mice treated with vehicle diet; WT-P021 = wild-type mice treated with P021 diet; Tg-Vh = 3xTg-AD mice treated with vehicle diet; Tg-P021 = 3xTg-AD mice treated with P021 diet</p></caption><graphic id="MO5" xlink:href="13024_2016_119_Fig5_HTML"></graphic></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>P021 treatment reduces soluble Aβ in 3xTg-AD mice. Reprinted from Kazim et al. [<xref ref-type="bibr" rid="CR99">99</xref>] with permission from Elsevier. <bold>a</bold>, <bold>b</bold> ELISA quantification of soluble and insoluble Aβ 1–40 and Aβ 1–42 in the cortex revealed significant reduction of soluble Aβ with P021 treatment in 15–16 month-old/6 months treatment group but not in 21–22 month old/12 months treatment group. No effect on insoluble Aβ was found. Quantification is shown as mean ± S.E.M. from Tg-Vh (<italic>n</italic> = 5–7) and Tg-P021 (<italic>n</italic> = 6–7). <bold>c</bold>, <bold>d</bold> Representative photomicrographs illustrating thioflavin S (TS)<sup>+</sup> plaque load in the CA1 and subiculum regions of the hippocampus from 15–16 month old/6 months treatment mice are shown. Quantification of TS<sup>+</sup> load is shown as mean ± S.E.M. from Tg-Vh (<italic>n</italic> = 7), and Tg-P021 (<italic>n</italic> = 7). <bold>e</bold>, <bold>f</bold> Representative photomicrographs illustrating TS<sup>+</sup> plaque load in the CA1 and subiculum regions of the hippocampus from 21–22 month old/12 months treatment mice are shown. Quantification of TS<sup>+</sup> load is shown as mean ± S.E.M. from Tg-Vh (<italic>n</italic> = 7), and Tg-P021 (<italic>n</italic> = 6–7). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01. <italic>Scale bar</italic> = 100 μm</p></caption><graphic id="MO6" xlink:href="13024_2016_119_Fig6_HTML"></graphic></fig><fig id="Fig7"><label>Fig. 7</label><caption><p>P021 treatment enhances dentate gyrus neurogenesis and rescues dendritic and synaptic loss in 3xTg-AD mice. Reprinted from Kazim et al. [<xref ref-type="bibr" rid="CR99">99</xref>] with permission from Elsevier. <bold>a</bold>-<bold>d</bold> DG neurogenesis, as evaluated by counting Ki-67 (cell proliferation maker) and doublecortin (DCX, marker for immature neurons) positive cells, was significantly deficient in 15–16 month-old 3xTg-AD mice, and was corrected by P021 treatment. <bold>a</bold>, <bold>c</bold> Representative photomicrographs illustrating Ki-67+/TOPRO and doublecortin (DCX) + cells in the DG of hippocampus from 15–16 month-old/6 months treatment mice. <bold>b</bold>, <bold>d</bold> Densitometric quantification data of Ki-67+ and DCX+ cells are shown as mean ± S.E.M. from WT-Vh (<italic>n</italic> = 6), Tg-Vh (<italic>n</italic> = 7) and Tg-P021 (<italic>n</italic> = 7), and WT-Vh (<italic>n</italic> = 5), Tg-Vh (<italic>n</italic> = 6), and Tg-P021 (<italic>n</italic> = 6), respectively. Arrow heads indicate positive cells. <bold>e</bold>-<bold>h</bold> The 15–16 month old 3xTg-AD mice showed significantly reduced MAP2 (dendritic marker) and synaptophysin (presynaptic marker) expression level (fluorescence intensity) in the CA3 and CA1 regions of the hippocampus, respectively. P021 treatment significantly ameliorated this deficit. <bold>e</bold> Representative photomicrographs illustrating MAP2 immunoreactivity in the CA3 region. <bold>f</bold> Densitometric quantification of the immunohistochemistry is shown as mean ± S.E.M. fromWT-Vh (<italic>n</italic> = 6), Tg-Vh (<italic>n</italic> = 7), and Tg-P021 (<italic>n</italic> = 7). <bold>g</bold> Representative photomicrographs illustrating synaptophysin immunoreactivity in the CA1 region. <bold>h</bold> Densitometric quantification of the immunohistochemistry is shown as mean ± S.E.M. from WT-Vh (<italic>n</italic> = 6), Tg-Vh (<italic>n</italic> = 6), and Tg-P021 (<italic>n</italic> = 6). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, and ***<italic>p</italic> &lt; 0.001. <italic>Scale bar</italic> = 100 μm</p></caption><graphic id="MO7" xlink:href="13024_2016_119_Fig7_HTML"></graphic></fig><fig id="Fig8"><label>Fig. 8</label><caption><p>Mechanism of the disease-modifying effect of P021 in AD. The CNTF small-molecule peptide mimetic compound, P021, increases BDNF expression which via the TrkB-PI3K-AKT pathway leads to inhibitory phosphorylation of GSK3β at Ser9 [<xref ref-type="bibr" rid="CR99">99</xref>]. GSK3β is major tau kinase and contributes to abnormal hyperphosphorylation of tau at several major sites, and also plays a role in the amyloidogenic processing of APP. P021, via decreasing the GSK3β activity, causes decrease in tau and Aβ pathologies</p></caption><graphic id="MO8" xlink:href="13024_2016_119_Fig8_HTML"></graphic></fig></p>
<p>The compound P021 has favorable pharmacokinetics for drug development including plasma half-life of &gt;3 h and stability of &gt;95 % and &gt;90 % in artificial intestinal fluid up till 2 h and in artificial gastric juice up till 30 min, respectively, and is BBB permeable [<xref ref-type="bibr" rid="CR99">99</xref>]. Up to 1 year of P021 administration did not induce any adverse effect in 3xTg-AD mice or in wild type control [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
</sec>
<sec id="Sec10">
<title>Conclusions</title>
<p>AD is a multifactorial and heterogeneous devastating neurodegenerative disorder which contributes significantly to health care burden worldwide, more so because of the lack of an effective therapy. Independent of the various etiopathogenic mechanisms involved in AD, the neurogenic and synaptic failure are a common feature of AD that play a pivotal role in cognitive dysfunction. The rationale for the use of neurotrophic factors based approach is quite strong by virtue of their well-established pro-neurogenic effects and synaptic repair potential. However, the unfavorable pharmacokinetics, poor brain penetration, and undesired adverse effects associated with the native neurotrophic factor molecules limit their clinical usage. Neurotrophic factor small-molecule mimetics offer a highly promising strategy to overcome these limitations for AD drug development. Preclinical studies have demonstrated therapeutic beneficial effects of several neurotrophic factor small-molecule mimetics particularly the BDNF and CNTF mimetics. These compounds are currently undergoing or will undergo in near-future human clinical trials to assess their therapeutic efficacy in human AD patients. Overall, the neurotrophic factor small-molecule mimetics based neuroregeneration and synaptic repair represents a highly promising therapeutic strategy for AD, and can lead to the development of an effective drug to rescue cognitive impairment.</p>
</sec>
</sec>
<sec id="Sec11">
<title>Abbreviations</title>
<p>3xTg-AD, triple transgenic Alzheimer’s disease mice; 7,8-DHF, 7,8-dihydroxyflavone; Ach, acetylcholine; AD, Alzheimer’s disease; APOE ε4, apolipoprotein E ε4; APP, amyloid β precursor protein; ARTN, artemin; Aβ, amyloid β; BBB, blood–brain barrier; BDNF, brain-derived neurotrophic factor; BMP, bone morphogenic protein; CaMKII, calcium/calmodulin activated protein kinase II; Cdk5, cyclin-dependent kinase 5; CERAD, consortium to establish a Registry for Alzheimer’s disease; ChAT, choline acetyltransferase; CNS, central nervous system; CNTF, ciliary neurotrophic factor; CNTFRα, ciliary neurotrophic factor receptor α; CTFβ, C-terminal fragment β; ERK, extracellular signal-regulated kinase; FGF2, fibroblast growth factor 2; GDNF, glial cell-derived neurotrophic factor; GFL, glial cell-derived neurotrophic factor family ligands; GFRα, glial cell-derived neurotrophic factor family receptor alpha; gp130, glycoprotein 130; GSK-3β, glycogen synthase kinase 3 β; IL-11, interleukin-11; IL-6, interleukin-6; LIF, leukemia inhibitory factor; LIFR, leukemia inhibitory factor β receptor; LTP, long-term potentiation; MAP, microtubule associated protein; MAPK, mitogen-activated protein kinase; MCI, mild cognitive impairment; NFTs, neurofibrillary tangles; NGF, nerve growth factor; NPCs, neural precursor cells; NRTN, neurturin; NT3, neurotrophin 3; NT4, neurotrophin 4; P021, peptide 021; P6, peptide 6; p75<sup>NTR</sup>, p75 neurotrophin receptor; PI3K, phosphoinositide 3-kinase; PKB/AKT, protein kinase B; PP2A, protein phosphatase 2A; PS1, presenilin 1; PS2, presenilin 2; pSer, phosphorylated serine; PSPN, persephin; pTau, abnormally hyperphosphorylated tau protein; pThr, phosphorylated threonine; RET, rearranged during transfection; TGFβ, tansforming growth factor β; Trk, tropomysin receptor kinase.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The work on neurotrophic factor small-molecule mimetics in our lab was supported by research grants from Alzheimer’s Association, USA; Alzheimer’s Drug Discovery Foundation (ADDF), USA; and EVER NeuroPharma GmbH, Unterach, Austria, and in part by the New York State Office of People with Developmental Disabilities. SFK is supported by a doctoral fellowship from SUNY Downstate/NYSIBR Program in Developmental Neuroscience.</p>
<p>We would like to acknowledge late Dr. Inge Grundke-Iqbal who initiated the work with neurotrophic factor small-molecule peptide mimetics in our lab. Dr. Grundke-Iqbal passed away on September 22, 2012. We would also like to acknowledge Dr. M. Omar Chohan, Dr. Julie Blanchard, Dr. Bin Li, and Dr. Silvia Bolognin who contributed significantly to the work on neurotrophic factor small-molecule mimetics in our lab. </p>
<sec id="FPar1">
<title>Authors’ contributions</title>
<p>SFK drafted the first version of this review. KI revised the manuscript for intellectual content. All authors read and approved the final manuscript.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p>KI has U.S. patents on CNTF small-molecule peptide mimetics for the treatment of AD and related neurodegenerative disorders.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gauthier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brayne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease</article-title>
<source/>Lancet
          <year>2011</year>
<volume>377</volume>
<fpage>1019</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(10)61349-9</pub-id>
<pub-id pub-id-type="pmid">21371747</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cornutiu</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The epidemiological scale of Alzheimer’s disease</article-title>
<source/>J Clin Med Res
          <year>2015</year>
<volume>7</volume>
<fpage>657</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.14740/jocmr2106w</pub-id>
<pub-id pub-id-type="pmid">26251678</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hebert</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Weuve</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scherr</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Alzheimer disease in the United States (2010–2050) estimated using the 2010 census</article-title>
<source/>Neurology
          <year>2013</year>
<volume>80</volume>
<fpage>1778</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e31828726f5</pub-id>
<pub-id pub-id-type="pmid">23390181</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alzheimer's</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease facts and figures</article-title>
<source/>Alzheimers Dement
          <year>2016</year>
<volume>2016</volume>
<fpage>12</fpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<mixed-citation publication-type="other">Prince MJ, Guerchet MM, Prina M. The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Geneva; World Health Organization. 2015. APA citation can be accessed at: (<ext-link ext-link-type="uri" xlink:href="https://kclpure.kcl.ac.uk/portal/en/publications/the-epidemiology-and-impact-of-dementia(538a75cb-1519-49d4-8876-92ae9cfc4151)/export.html">https://kclpure.kcl.ac.uk/portal/en/publications/the-epidemiology-and-impact-of-dementia(538a75cb-1519-49d4-8876-92ae9cfc4151)/export.html</ext-link>)</mixed-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Opportunities and challenges in developing Alzheimer disease therapeutics</article-title>
<source/>Acta Neuropathol
          <year>2011</year>
<volume>122</volume>
<fpage>543</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-011-0878-z</pub-id>
<pub-id pub-id-type="pmid">21959585</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hebert</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Scherr</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Bienias</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Alzheimer disease in the US population: prevalence estimates using the 2000 census</article-title>
<source/>Arch Neurol
          <year>2003</year>
<volume>60</volume>
<fpage>1119</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.60.8.1119</pub-id>
<pub-id pub-id-type="pmid">12925369</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<mixed-citation publication-type="other">Prince M, Guerchet, M, Prina, M. Policy Brief for Heads of Government: The Global Impact of Dementia 2013–2050. London: Alzheimer's Disease Internationall; 2013. APA citation can be accessed at: (<ext-link ext-link-type="uri" xlink:href="https://kclpure.kcl.ac.uk/portal/en/publications/the-global-impact-of-dementia-20132050(893055ed-e533-4d88-9d15-3aa4abdfcc20)/export.html">https://kclpure.kcl.ac.uk/portal/en/publications/the-global-impact-of-dementia-20132050(893055ed-e533-4d88-9d15-3aa4abdfcc20)/export.html</ext-link>).</mixed-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burns</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iliffe</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease</article-title>
<source/>BMJ
          <year>2009</year>
<volume>338</volume>
<fpage>b158</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.b158</pub-id>
<pub-id pub-id-type="pmid">19196745</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease</article-title>
<source/>N Engl J Med
          <year>2004</year>
<volume>351</volume>
<fpage>56</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra040223</pub-id>
<pub-id pub-id-type="pmid">15229308</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grady</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Haxby</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sundaram</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schapiro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Friedland</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type</article-title>
<source/>J Clin Exp Neuropsychol
          <year>1988</year>
<volume>10</volume>
<fpage>576</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1080/01688638808402796</pub-id>
<pub-id pub-id-type="pmid">3265710</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glenner</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CW</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title>
<source/>Biochem Biophys Res Commun
          <year>1984</year>
<volume>120</volume>
<fpage>885</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-291X(84)80190-4</pub-id>
<pub-id pub-id-type="pmid">6375662</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Quinlan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>LI</given-names>
</name>
</person-group>
<article-title>Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1986</year>
<volume>83</volume>
<fpage>4913</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.83.13.4913</pub-id>
<pub-id pub-id-type="pmid">3088567</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crews</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of neurodegeneration in Alzheimer’s disease</article-title>
<source/>Hum Mol Genet
          <year>2010</year>
<volume>19</volume>
<fpage>R12</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddq160</pub-id>
<pub-id pub-id-type="pmid">20413653</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sumpter</surname>
<given-names>PQ</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>PO</given-names>
</name>
</person-group>
<article-title>A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease</article-title>
<source/>J Neurol Sci
          <year>1987</year>
<volume>78</volume>
<fpage>151</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/0022-510X(87)90057-8</pub-id>
<pub-id pub-id-type="pmid">3572454</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demars</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Gadadhar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lazarov</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Impaired neurogenesis is an early event in the etiology of familial Alzheimer’s disease in transgenic mice</article-title>
<source/>J Neurosci Res
          <year>2010</year>
<volume>88</volume>
<fpage>2103</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.22387</pub-id>
<pub-id pub-id-type="pmid">20209626</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yamamori</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tatebayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shafit-Zagardo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tanimukai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Failure of neuronal maturation in Alzheimer disease dentate gyrus</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2008</year>
<volume>67</volume>
<fpage>78</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1097/nen.0b013e318160c5db</pub-id>
<pub-id pub-id-type="pmid">18091557</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Adult hippocampal neurogenesis and its role in Alzheimer’s disease</article-title>
<source/>Mol Neurodegeneration
          <year>2011</year>
<volume>6</volume>
<fpage>85</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1326-6-85</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease-related alterations in synaptic density: neocortex and hippocampus</article-title>
<source/>J Alzheimers Dis
          <year>2006</year>
<volume>9</volume>
<fpage>101</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">16914849</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Mufson</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment</article-title>
<source/>Neurology
          <year>2007</year>
<volume>68</volume>
<fpage>1501</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000260698.46517.8f</pub-id>
<pub-id pub-id-type="pmid">17470753</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Mufson</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment</article-title>
<source/>Neurobiol Aging
          <year>2006</year>
<volume>27</volume>
<fpage>1372</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.09.012</pub-id>
<pub-id pub-id-type="pmid">16289476</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease is a synaptic failure</article-title>
<source/>Science
          <year>2002</year>
<volume>298</volume>
<fpage>789</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1126/science.1074069</pub-id>
<pub-id pub-id-type="pmid">12399581</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shruster</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Melamed</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Offen</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neurogenesis in the aged and neurodegenerative brain</article-title>
<source/>Apoptosis
          <year>2010</year>
<volume>15</volume>
<fpage>1415</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1007/s10495-010-0491-y</pub-id>
<pub-id pub-id-type="pmid">20339917</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sze</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kawas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mouton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease</article-title>
<source/>J Neuropathol Exp Neurol
          <year>1997</year>
<volume>56</volume>
<fpage>933</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1097/00005072-199708000-00011</pub-id>
<pub-id pub-id-type="pmid">9258263</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terry</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Butters</surname>
<given-names>N</given-names>
</name>
<name>
<surname>DeTeresa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment</article-title>
<source/>Ann Neurol
          <year>1991</year>
<volume>30</volume>
<fpage>572</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410300410</pub-id>
<pub-id pub-id-type="pmid">1789684</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aimone</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Adult neurogenesis: integrating theories and separating functions</article-title>
<source/>Trends Cogn Sci
          <year>2010</year>
<volume>14</volume>
<fpage>325</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.tics.2010.04.003</pub-id>
<pub-id pub-id-type="pmid">20471301</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aimone</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Wiles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Potential role for adult neurogenesis in the encoding of time in new memories</article-title>
<source/>Nat Neurosci
          <year>2006</year>
<volume>9</volume>
<fpage>723</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/nn1707</pub-id>
<pub-id pub-id-type="pmid">16732202</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Aimone</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?</article-title>
<source/>Nat Rev Neurosci
          <year>2010</year>
<volume>11</volume>
<fpage>339</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2822</pub-id>
<pub-id pub-id-type="pmid">20354534</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neves</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Bliss</surname>
<given-names>TV</given-names>
</name>
</person-group>
<article-title>Synaptic plasticity, memory and the hippocampus: a neural network approach to causality</article-title>
<source/>Nat Rev Neurosci
          <year>2008</year>
<volume>9</volume>
<fpage>65</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2303</pub-id>
<pub-id pub-id-type="pmid">18094707</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahay</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scobie</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>O’Carroll</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kheirbek</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Burghardt</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Fenton</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Dranovsky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation</article-title>
<source/>Nature
          <year>2011</year>
<volume>472</volume>
<fpage>466</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1038/nature09817</pub-id>
<pub-id pub-id-type="pmid">21460835</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battaglia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Ghilardi</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Gashi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Quartarone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Cortical plasticity in Alzheimer’s disease in humans and rodents</article-title>
<source/>Biol Psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>1405</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.02.027</pub-id>
<pub-id pub-id-type="pmid">17651702</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arendt</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Synaptic degeneration in Alzheimer’s disease</article-title>
<source/>Acta Neuropathol
          <year>2009</year>
<volume>118</volume>
<fpage>167</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-009-0536-x</pub-id>
<pub-id pub-id-type="pmid">19390859</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity</article-title>
<source/>Ann Neurol
          <year>1990</year>
<volume>27</volume>
<fpage>457</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410270502</pub-id>
<pub-id pub-id-type="pmid">2360787</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Styren</surname>
<given-names>SD</given-names>
</name>
</person-group>
<article-title>Structural correlates of cognition in dementia: quantification and assessment of synapse change</article-title>
<source/>Neurodegeneration
          <year>1996</year>
<volume>5</volume>
<fpage>417</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1006/neur.1996.0056</pub-id>
<pub-id pub-id-type="pmid">9117556</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mallory</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DeTeresa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Alford</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terry</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Synaptic and neuritic alterations during the progression of Alzheimer’s disease</article-title>
<source/>Neurosci Lett
          <year>1994</year>
<volume>174</volume>
<fpage>67</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/0304-3940(94)90121-X</pub-id>
<pub-id pub-id-type="pmid">7970158</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kazim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Bolognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer’s disease and related neurodegenerative conditions</article-title>
<source/>Neural Regen Res
          <year>2014</year>
<volume>9</volume>
<fpage>1518</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.4103/1673-5374.139477</pub-id>
<pub-id pub-id-type="pmid">25317168</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<mixed-citation publication-type="other">About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson). Alzheimer disease and associated disorders 1987, 1:3–8</mixed-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease, a multifactorial disorder seeking multitherapies</article-title>
<source/>Alzheimers Dement
          <year>2010</year>
<volume>6</volume>
<fpage>420</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/j.jalz.2010.04.006</pub-id>
<pub-id pub-id-type="pmid">20813343</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bird</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Genetic aspects of Alzheimer disease</article-title>
<source/>Genet Med
          <year>2008</year>
<volume>10</volume>
<fpage>231</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1097/GIM.0b013e31816b64dc</pub-id>
<pub-id pub-id-type="pmid">18414205</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerreiro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Genetics of Alzheimer’s disease</article-title>
<source/>Neurotherapeutics
          <year>2014</year>
<volume>11</volume>
<fpage>732</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-014-0295-9</pub-id>
<pub-id pub-id-type="pmid">25113539</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corder</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Schmechel</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Gaskell</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Roses</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Haines</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pericak-Vance</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families</article-title>
<source/>Science
          <year>1993</year>
<volume>261</volume>
<fpage>921</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="doi">10.1126/science.8346443</pub-id>
<pub-id pub-id-type="pmid">8346443</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardy</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: the amyloid cascade hypothesis</article-title>
<source/>Science
          <year>1992</year>
<volume>256</volume>
<fpage>184</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1126/science.1566067</pub-id>
<pub-id pub-id-type="pmid">1566067</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lemaire</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Unterbeck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salbaum</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Masters</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Grzeschik</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Multhaup</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beyreuther</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Muller-Hill</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor</article-title>
<source/>Nature
          <year>1987</year>
<volume>325</volume>
<fpage>733</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1038/325733a0</pub-id>
<pub-id pub-id-type="pmid">2881207</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masters</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Simms</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Weinman</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Multhaup</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Beyreuther</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Amyloid plaque core protein in Alzheimer disease and down syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1985</year>
<volume>82</volume>
<fpage>4245</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.82.12.4245</pub-id>
<pub-id pub-id-type="pmid">3159021</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Barlow</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Chromy</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Freed</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liosatos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Rozovsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Trommer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Viola</surname>
<given-names>KL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1998</year>
<volume>95</volume>
<fpage>6448</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.11.6448</pub-id>
<pub-id pub-id-type="pmid">9600986</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Klyubin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fadeeva</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Anwyl</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Rowan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo</article-title>
<source/>Nature
          <year>2002</year>
<volume>416</volume>
<fpage>535</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/416535a</pub-id>
<pub-id pub-id-type="pmid">11932745</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bliss</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>A synaptic model of memory: long-term potentiation in the hippocampus</article-title>
<source/>Nature
          <year>1993</year>
<volume>361</volume>
<fpage>31</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/361031a0</pub-id>
<pub-id pub-id-type="pmid">8421494</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>McLachlan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease in down’s syndrome: clinicopathologic studies</article-title>
<source/>Neurology
          <year>1985</year>
<volume>35</volume>
<fpage>957</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.35.7.957</pub-id>
<pub-id pub-id-type="pmid">3159974</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karlinsky</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease in down’s syndrome</article-title>
<source/>A review J Am Geriatr Soc
          <year>1986</year>
<volume>34</volume>
<fpage>728</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1111/j.1532-5415.1986.tb04304.x</pub-id>
<pub-id pub-id-type="pmid">2944942</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<mixed-citation publication-type="other">Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–9. (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/3331112">http://www.ncbi.nlm.nih.gov/pubmed/3331112</ext-link>), PMID: 3331112. It's an English translation of original case by Alois Alzheimer.</mixed-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Shelanski</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Brostoff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liwnicz</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Terry</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Protein changes in senile dementia</article-title>
<source/>Brain Res
          <year>1974</year>
<volume>77</volume>
<fpage>337</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(74)90798-7</pub-id>
<pub-id pub-id-type="pmid">4604978</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration</article-title>
<source/>Eur J Neurosci
          <year>2007</year>
<volume>25</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.05226.x</pub-id>
<pub-id pub-id-type="pmid">17241267</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase</article-title>
<source/>FEBS Lett
          <year>1998</year>
<volume>436</volume>
<fpage>28</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(98)01090-4</pub-id>
<pub-id pub-id-type="pmid">9771888</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alonso Adel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>El-Akkad</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Khatoon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tau pathology in Alzheimer disease and other tauopathies</article-title>
<source/>Biochim Biophys Acta
          <year>2005</year>
<volume>1739</volume>
<fpage>198</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2004.09.008</pub-id>
<pub-id pub-id-type="pmid">15615638</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Zaidi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain</article-title>
<source/>J Neurochem
          <year>1995</year>
<volume>65</volume>
<fpage>732</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.1995.65020732.x</pub-id>
<pub-id pub-id-type="pmid">7616230</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Phosphoprotein phosphatase activities in Alzheimer disease brain</article-title>
<source/>J Neurochem
          <year>1993</year>
<volume>61</volume>
<fpage>921</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.1993.tb03603.x</pub-id>
<pub-id pub-id-type="pmid">8395566</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>CX</given-names>
</name>
</person-group>
<article-title>Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation</article-title>
<source/>Eur J Neurosci
          <year>2005</year>
<volume>22</volume>
<fpage>1942</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04391.x</pub-id>
<pub-id pub-id-type="pmid">16262633</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Alafuzoff</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Bouras</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Castellani</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Del Tredici</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2012</year>
<volume>71</volume>
<fpage>362</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0b013e31825018f7</pub-id>
<pub-id pub-id-type="pmid">22487856</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Del Tredici</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The pathological process underlying Alzheimer’s disease in individuals under thirty</article-title>
<source/>Acta Neuropathol
          <year>2011</year>
<volume>121</volume>
<fpage>171</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-010-0789-4</pub-id>
<pub-id pub-id-type="pmid">21170538</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thal</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Ghebremedhin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Del Tredici</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2011</year>
<volume>70</volume>
<fpage>960</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0b013e318232a379</pub-id>
<pub-id pub-id-type="pmid">22002422</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riley</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Jicha</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abner</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Stiles</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Kryscio</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Van Eldik</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>Prediction of preclinical Alzheimer’s disease: longitudinal rates of change in cognition</article-title>
<source/>J Alzheimers Dis
          <year>2011</year>
<volume>25</volume>
<fpage>707</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">21498903</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Wekstein</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Ashford</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Markesbery</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Preclinical” AD revisited: neuropathology of cognitively normal older adults</article-title>
<source/>Neurol
          <year>2000</year>
<volume>55</volume>
<fpage>370</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.55.3.370</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bachstetter</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Van Eldik</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in ten mouse models</article-title>
<source/>Frontiers in Genetics
          <year>2014</year>
<volume>5</volume>
<fpage>88</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2014.00088</pub-id>
<pub-id pub-id-type="pmid">24795750</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belleville</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sylvain-Roy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>de Boysson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menard</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Characterizing the memory changes in persons with mild cognitive impairment</article-title>
<source/>Prog Brain Res
          <year>2008</year>
<volume>169</volume>
<fpage>365</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/S0079-6123(07)00023-4</pub-id>
<pub-id pub-id-type="pmid">18394487</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>UA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Provenzano</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Profaci</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Sloan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duff</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer’s disease</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<fpage>304</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3606</pub-id>
<pub-id pub-id-type="pmid">24362760</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Drouet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Witter</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Clelland</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duff</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Trans-synaptic spread of tau pathology in vivo</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e31302</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0031302</pub-id>
<pub-id pub-id-type="pmid">22312444</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reitz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brickman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Manly</surname>
<given-names>J</given-names>
</name>
<name>
<surname>DeCarli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Linking hippocampal structure and function to memory performance in an aging population</article-title>
<source/>Arch Neurol
          <year>2009</year>
<volume>66</volume>
<fpage>1385</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">19901171</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Small</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Isolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability</article-title>
<source/>Neuron
          <year>2014</year>
<volume>84</volume>
<fpage>32</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2014.08.030</pub-id>
<pub-id pub-id-type="pmid">25277453</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maruff</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The neuropsychology of preclinical Alzheimer’s disease and mild cognitive impairment</article-title>
<source/>Neurosci Biobehav Rev
          <year>2000</year>
<volume>24</volume>
<fpage>365</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/S0149-7634(00)00012-9</pub-id>
<pub-id pub-id-type="pmid">10781696</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Pankratz</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Negash</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Machulda</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ferman</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ivnik</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?</article-title>
<source/>Neurology
          <year>2007</year>
<volume>69</volume>
<fpage>133</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000265594.23511.16</pub-id>
<pub-id pub-id-type="pmid">17620545</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bondi</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Jak</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Delano-Wood</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Delis</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Salmon</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>Neuropsychological contributions to the early identification of Alzheimer’s disease</article-title>
<source/>Neuropsychol Rev
          <year>2008</year>
<volume>18</volume>
<fpage>73</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1007/s11065-008-9054-1</pub-id>
<pub-id pub-id-type="pmid">18347989</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storandt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI</article-title>
<source/>Neurology
          <year>2006</year>
<volume>67</volume>
<fpage>467</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000228231.26111.6e</pub-id>
<pub-id pub-id-type="pmid">16894109</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Twamley</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Ropacki</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bondi</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Neuropsychological and neuroimaging changes in preclinical Alzheimer’s disease</article-title>
<source/>J Int Neuropsychol Soc
          <year>2006</year>
<volume>12</volume>
<fpage>707</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1017/S1355617706060863</pub-id>
<pub-id pub-id-type="pmid">16961952</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuokko</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mild cognitive impairment and everyday functioning in older adults</article-title>
<source/>Neurocase
          <year>2005</year>
<volume>11</volume>
<fpage>40</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1080/13554790490896802</pub-id>
<pub-id pub-id-type="pmid">15804923</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKhann</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Knopman</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Chertkow</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>CR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Kawas</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Klunk</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Koroshetz</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Manly</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>
<source/>Alzheimers Dement
          <year>2011</year>
<volume>7</volume>
<fpage>263</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id>
<pub-id pub-id-type="pmid">21514250</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruel-Jungerman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rampon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Laroche</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses</article-title>
<source/>Rev Neurosci
          <year>2007</year>
<volume>18</volume>
<fpage>93</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1515/REVNEURO.2007.18.2.93</pub-id>
<pub-id pub-id-type="pmid">17593874</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<mixed-citation publication-type="other">Abrous DN, Wojtowicz JM. Interaction between neurogenesis and hippocampal memory system: New Vistas. Cold Spring Harb Perspect Biol. 2015;7.</mixed-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drapeau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Aurousseau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Le Moal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Piazza</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Abrous</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>14385</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.2334169100</pub-id>
<pub-id pub-id-type="pmid">14614143</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupret</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Revest</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Koehl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ichas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Giorgi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Costet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Abrous</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Piazza</surname>
<given-names>PV</given-names>
</name>
</person-group>
<article-title>Spatial relational memory requires hippocampal adult neurogenesis</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<fpage>e1959</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0001959</pub-id>
<pub-id pub-id-type="pmid">18509506</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leuner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shors</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Is there a link between adult neurogenesis and learning?</article-title>
<source/>Hippocampus
          <year>2006</year>
<volume>16</volume>
<fpage>216</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1002/hipo.20153</pub-id>
<pub-id pub-id-type="pmid">16421862</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lledo</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grubb</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Adult neurogenesis and functional plasticity in neuronal circuits</article-title>
<source/>Nat Rev Neurosci
          <year>2006</year>
<volume>7</volume>
<fpage>179</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1867</pub-id>
<pub-id pub-id-type="pmid">16495940</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Saxe</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Gallina</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Adult-born hippocampal dentate granule cells undergoing maturation modulate learning and memory in the brain</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>13532</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3362-09.2009</pub-id>
<pub-id pub-id-type="pmid">19864566</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shors</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>From stem cells to grandmother cells: how neurogenesis relates to learning and memory</article-title>
<source/>Cell Stem Cell
          <year>2008</year>
<volume>3</volume>
<fpage>253</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2008.08.010</pub-id>
<pub-id pub-id-type="pmid">18786413</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Michell</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Neurogenesis in diseases of the central nervous system</article-title>
<source/>Stem Cells Dev
          <year>2006</year>
<volume>15</volume>
<fpage>359</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1089/scd.2006.15.359</pub-id>
<pub-id pub-id-type="pmid">16846374</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonfanti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peretto</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Adult neurogenesis in mammals--a theme with many variations</article-title>
<source/>Eur J Neurosci
          <year>2011</year>
<volume>34</volume>
<fpage>930</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07832.x</pub-id>
<pub-id pub-id-type="pmid">21929626</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Neurogenesis in the adult brain</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>612</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">11826087</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inokuchi</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Adult neurogenesis and modulation of neural circuit function</article-title>
<source/>Curr Opin Neurobiol
          <year>2011</year>
<volume>21</volume>
<fpage>360</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2011.02.006</pub-id>
<pub-id pub-id-type="pmid">21367599</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kempermann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Neurogenesis in the adult hippocampus</article-title>
<source/>Novartis Found Symp
          <year>2000</year>
<volume>231</volume>
<fpage>220</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1002/0470870834.ch14</pub-id>
<pub-id pub-id-type="pmid">11131541</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Development of neural circuits in the adult hippocampus</article-title>
<source/>Curr Top Dev Biol
          <year>2009</year>
<volume>87</volume>
<fpage>149</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/S0070-2153(09)01205-8</pub-id>
<pub-id pub-id-type="pmid">19427519</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grote</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Hannan</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Regulators of adult neurogenesis in the healthy and diseased brain</article-title>
<source/>Clin Exp Pharmacol Physiol
          <year>2007</year>
<volume>34</volume>
<fpage>533</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1681.2007.04610.x</pub-id>
<pub-id pub-id-type="pmid">17439429</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verret</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jankowsky</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Borchelt</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Rampon</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Alzheimer’s-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>6771</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5564-06.2007</pub-id>
<pub-id pub-id-type="pmid">17581964</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verret</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Trouche</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zerwas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rampon</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Hippocampal neurogenesis during normal and pathological aging</article-title>
<source/>Psychoneuroendocrinology
          <year>2007</year>
<volume>32</volume>
<issue>Suppl 1</issue>
<fpage>S26</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2007.04.014</pub-id>
<pub-id pub-id-type="pmid">17629417</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Galvan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>XO</given-names>
</name>
<name>
<surname>Gorostiza</surname>
<given-names>OF</given-names>
</name>
<name>
<surname>Bredesen</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw, Ind) mice</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<fpage>13363</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0403678101</pub-id>
<pub-id pub-id-type="pmid">15340159</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knobloch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mansuy</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>Dendritic spine loss and synaptic alterations in Alzheimer’s disease</article-title>
<source/>Mol Neurobiol
          <year>2008</year>
<volume>37</volume>
<fpage>73</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-008-8018-z</pub-id>
<pub-id pub-id-type="pmid">18438727</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Quantitative assessment of cortical synaptic density in Alzheimer’s disease</article-title>
<source/>Neurobiol Aging
          <year>1990</year>
<volume>11</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/0197-4580(90)90059-9</pub-id>
<pub-id pub-id-type="pmid">2325814</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheff</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies</article-title>
<source/>Neurobiol Aging
          <year>2003</year>
<volume>24</volume>
<fpage>1029</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.08.002</pub-id>
<pub-id pub-id-type="pmid">14643375</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Praag</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schinder</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Christie</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Toni</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Functional neurogenesis in the adult hippocampus</article-title>
<source/>Nature
          <year>2002</year>
<volume>415</volume>
<fpage>1030</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1038/4151030a</pub-id>
<pub-id pub-id-type="pmid">11875571</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wanka</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Cardenas-Aguayo Mdel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice</article-title>
<source/>Acta Neuropathol
          <year>2010</year>
<volume>120</volume>
<fpage>605</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-010-0734-6</pub-id>
<pub-id pub-id-type="pmid">20697724</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease</article-title>
<source/>Neurobiol Dis
          <year>2014</year>
<volume>71</volume>
<fpage>110</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.07.001</pub-id>
<pub-id pub-id-type="pmid">25046994</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chevallier</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Soriano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>EH</given-names>
</name>
</person-group>
<article-title>Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation</article-title>
<source/>Am J Pathol
          <year>2005</year>
<volume>167</volume>
<fpage>151</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)62962-8</pub-id>
<pub-id pub-id-type="pmid">15972961</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Goico</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Csernansky</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Bertchume</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Csernansky</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress</article-title>
<source/>Neurosci
          <year>2004</year>
<volume>127</volume>
<fpage>601</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.05.040</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donovan</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Yazdani</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Norris</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Games</surname>
<given-names>D</given-names>
</name>
<name>
<surname>German</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Eisch</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer’s disease</article-title>
<source/>J Comp Neurol
          <year>2006</year>
<volume>495</volume>
<fpage>70</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1002/cne.20840</pub-id>
<pub-id pub-id-type="pmid">16432899</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>6498</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1001422107</pub-id>
<pub-id pub-id-type="pmid">20231471</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gluck</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Younkin</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Younkin</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>DeGasperi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gama Sosa</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Robakis</surname>
<given-names>NK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice</article-title>
<source/>Exp Neurol
          <year>2004</year>
<volume>188</volume>
<fpage>224</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2004.04.002</pub-id>
<pub-id pub-id-type="pmid">15246822</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enciu</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nicolescu</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Manole</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Muresanu</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Popescu</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Popescu</surname>
<given-names>BO</given-names>
</name>
</person-group>
<article-title>Neuroregeneration in neurodegenerative disorders</article-title>
<source/>BMC Neurol
          <year>2011</year>
<volume>11</volume>
<fpage>75</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2377-11-75</pub-id>
<pub-id pub-id-type="pmid">21699711</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<mixed-citation publication-type="other">Hunsberger JG, Rao M, Kurtzberg J, Bulte JW, Atala A, LaFerla FM, Greely HT, Sawa A, Gandy S, Schneider LS, Doraiswamy PM. Accelerating stem cell trials for Alzheimer’s disease. Lancet Neurol 2015. doi: 10.1016/S1474-4422(15)00332-4.</mixed-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>How close is the stem cell cure to the Alzheimer’s disease: Future and beyond?</article-title>
<source/>Neural Regen Res
          <year>2012</year>
<volume>7</volume>
<fpage>66</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">25806061</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blurton-Jones</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitazawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martinez-Coria</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Loring</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<fpage>13594</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0901402106</pub-id>
<pub-id pub-id-type="pmid">19633196</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiyota</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ingraham</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikezu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<fpage>E1339</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1102349108</pub-id>
<pub-id pub-id-type="pmid">22042871</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagahara</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tsukada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Shaked</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blesch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease</article-title>
<source/>Nat Med
          <year>2009</year>
<volume>15</volume>
<fpage>331</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1038/nm.1912</pub-id>
<pub-id pub-id-type="pmid">19198615</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Youssef</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Utvik</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Florent-Bechard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barthelemy</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Malaplate-Armand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kriem</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stenger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koziel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer’s disease</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>7516</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4182-09.2010</pub-id>
<pub-id pub-id-type="pmid">20519526</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbacid</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Neurotrophic factors and their receptors</article-title>
<source/>Curr Opin Cell Biol
          <year>1995</year>
<volume>7</volume>
<fpage>148</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/0955-0674(95)80022-0</pub-id>
<pub-id pub-id-type="pmid">7612265</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nagappan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Nathan</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Wren</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases</article-title>
<source/>Nat Rev Neurosci
          <year>2013</year>
<volume>14</volume>
<fpage>401</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3505</pub-id>
<pub-id pub-id-type="pmid">23674053</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semkova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Krieglstein</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors</article-title>
<source/>Brain Res Brain Res Rev
          <year>1999</year>
<volume>30</volume>
<fpage>176</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0173(99)00013-2</pub-id>
<pub-id pub-id-type="pmid">10525174</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chao</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Neurotrophins and their receptors: a convergence point for many signalling pathways</article-title>
<source/>Nat Rev Neurosci
          <year>2003</year>
<volume>4</volume>
<fpage>299</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1078</pub-id>
<pub-id pub-id-type="pmid">12671646</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Heese</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hulette</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas</article-title>
<source/>Arch Neurol
          <year>2000</year>
<volume>57</volume>
<fpage>846</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.57.6.846</pub-id>
<pub-id pub-id-type="pmid">10867782</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fukumoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Orne</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klucken</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Raju</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vanderburg</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Ingelsson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms</article-title>
<source/>Exp Neurol
          <year>2005</year>
<volume>194</volume>
<fpage>91</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2005.01.026</pub-id>
<pub-id pub-id-type="pmid">15899246</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalski</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fahnestock</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease</article-title>
<source/>Brain Res Mol Brain Res
          <year>2003</year>
<volume>111</volume>
<fpage>148</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/S0169-328X(03)00003-2</pub-id>
<pub-id pub-id-type="pmid">12654514</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Hains</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Armanini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laramee</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Winslow</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease</article-title>
<source/>Neuron
          <year>1991</year>
<volume>7</volume>
<fpage>695</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1016/0896-6273(91)90273-3</pub-id>
<pub-id pub-id-type="pmid">1742020</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice</article-title>
<source/>J Neurochem
          <year>2002</year>
<volume>82</volume>
<fpage>1367</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01085.x</pub-id>
<pub-id pub-id-type="pmid">12354284</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vilar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mira</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Regulation of neurogenesis by neurotrophins during adulthood: expected and unexpected roles</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>26</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00026</pub-id>
<pub-id pub-id-type="pmid">26903794</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons</article-title>
<source/>Nat Neurosci
          <year>2010</year>
<volume>13</volume>
<fpage>302</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2505</pub-id>
<pub-id pub-id-type="pmid">20173744</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schuman</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus</article-title>
<source/>Science
          <year>1995</year>
<volume>267</volume>
<fpage>1658</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1126/science.7886457</pub-id>
<pub-id pub-id-type="pmid">7886457</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korte</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bonhoeffer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schuman</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A role for BDNF in the late-phase of hippocampal long-term potentiation</article-title>
<source/>Neuropharmacol
          <year>1998</year>
<volume>37</volume>
<fpage>553</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0028-3908(98)00035-5</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory?</article-title>
<source/>Neurobiol Learn Mem
          <year>2008</year>
<volume>89</volume>
<fpage>312</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.nlm.2007.08.018</pub-id>
<pub-id pub-id-type="pmid">17942328</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mufson</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Weingartner</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Skau</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Crutcher</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis</article-title>
<source/>J Neurosci
          <year>1995</year>
<volume>15</volume>
<fpage>6213</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">7666203</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilcock</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>The cholinergic hypothesis of Alzheimer’s disease: a review of progress</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1999</year>
<volume>66</volume>
<fpage>137</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.66.2.137</pub-id>
<pub-id pub-id-type="pmid">10071091</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iulita</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Cuello</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Nerve growth factor metabolic dysfunction in Alzheimer’s disease and down syndrome</article-title>
<source/>Trends Pharmacol Sci
          <year>2014</year>
<volume>35</volume>
<fpage>338</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2014.04.010</pub-id>
<pub-id pub-id-type="pmid">24962069</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>NGF and the treatment of Alzheimer’s disease</article-title>
<source/>Exp Neurol
          <year>1993</year>
<volume>124</volume>
<fpage>5</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1006/exnr.1993.1167</pub-id>
<pub-id pub-id-type="pmid">8282080</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuszynski</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Barba</surname>
<given-names>D</given-names>
</name>
<name>
<surname>HS</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Bakay</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Pay</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kobalka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nagahara</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease</article-title>
<source/>JAMA Neurol
          <year>2015</year>
<volume>72</volume>
<fpage>1139</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2015.1807</pub-id>
<pub-id pub-id-type="pmid">26302439</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Airaksinen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Saarma</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The GDNF family: signalling, biological functions and therapeutic value</article-title>
<source/>Nat Rev Neurosci
          <year>2002</year>
<volume>3</volume>
<fpage>383</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1038/nrn812</pub-id>
<pub-id pub-id-type="pmid">11988777</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>He</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Deficiency of GDNF receptor GFRalpha1 in Alzheimer’s neurons results in neuronal death</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>13127</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2582-13.2014</pub-id>
<pub-id pub-id-type="pmid">25253858</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Revilla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ursulet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alvarez-Lopez</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Castro-Freire</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perpina</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Garcia-Mesa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bortolozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gimenez-Llort</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaliman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cristofol</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lenti-GDNF gene therapy protects against Alzheimer’s disease-like neuropathology in 3xTg-AD mice and MC65 cells</article-title>
<source/>CNS Neurosci Ther
          <year>2014</year>
<volume>20</volume>
<fpage>961</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1111/cns.12312</pub-id>
<pub-id pub-id-type="pmid">25119316</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ip</surname>
<given-names>NY</given-names>
</name>
</person-group>
<article-title>The neurotrophins and neuropoietic cytokines: two families of growth factors acting on neural and hematopoietic cells</article-title>
<source/>Ann N Y Acad Sci
          <year>1998</year>
<volume>840</volume>
<fpage>97</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09553.x</pub-id>
<pub-id pub-id-type="pmid">9629241</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stolp</surname>
<given-names>HB</given-names>
</name>
</person-group>
<article-title>Neuropoietic cytokines in normal brain development and neurodevelopmental disorders</article-title>
<source/>Mol Cell Neurosci
          <year>2013</year>
<volume>53</volume>
<fpage>63</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2012.08.009</pub-id>
<pub-id pub-id-type="pmid">22926235</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adachi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takanaga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kunimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Asou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Influence of LIF and BMP-2 on differentiation and development of glial cells in primary cultures of embryonic rat cerebral hemisphere</article-title>
<source/>J Neurosci Res
          <year>2005</year>
<volume>79</volume>
<fpage>608</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.20373</pub-id>
<pub-id pub-id-type="pmid">15678513</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Wnt signaling regulates the sequential onset of neurogenesis and gliogenesis via induction of BMPs</article-title>
<source/>Genes Cells
          <year>2005</year>
<volume>10</volume>
<fpage>777</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2443.2005.00876.x</pub-id>
<pub-id pub-id-type="pmid">16098141</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowitch</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kriegstein</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Developmental genetics of vertebrate glial-cell specification</article-title>
<source/>Nature
          <year>2010</year>
<volume>468</volume>
<fpage>214</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1038/nature09611</pub-id>
<pub-id pub-id-type="pmid">21068830</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senaldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Varnum</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Sarmiento</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Starnes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lile</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scully</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McNinch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shaklee</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1999</year>
<volume>96</volume>
<fpage>11458</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.20.11458</pub-id>
<pub-id pub-id-type="pmid">10500198</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yourey</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Gohari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zukauskas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ruben</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alderson</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Computational EST database analysis identifies a novel member of the neuropoietic cytokine family</article-title>
<source/>Biochem Biophys Res Commun
          <year>1999</year>
<volume>262</volume>
<fpage>132</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1999.1181</pub-id>
<pub-id pub-id-type="pmid">10448081</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Role of ciliary neurotrophic factor in the proliferation and differentiation of neural stem cells</article-title>
<source/>J Alzheimers Dis
          <year>2013</year>
<volume>37</volume>
<fpage>587</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">23948898</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emsley</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Hagg</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Endogenous and exogenous ciliary neurotrophic factor enhances forebrain neurogenesis in adult mice</article-title>
<source/>Exp Neurol
          <year>2003</year>
<volume>183</volume>
<fpage>298</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-4886(03)00129-8</pub-id>
<pub-id pub-id-type="pmid">14552871</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Habas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hetman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hagg</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>2231</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3574-07.2008</pub-id>
<pub-id pub-id-type="pmid">18305256</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aldrich</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Stahl</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Taga</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Yancopoulos</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor</article-title>
<source/>Science
          <year>1993</year>
<volume>260</volume>
<fpage>1805</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1126/science.8390097</pub-id>
<pub-id pub-id-type="pmid">8390097</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sendtner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Thoenen</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Ciliary neurotrophic factor</article-title>
<source/>J Neurobiol
          <year>1994</year>
<volume>25</volume>
<fpage>1436</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1002/neu.480251110</pub-id>
<pub-id pub-id-type="pmid">7852996</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasquin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gauchat</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Ciliary neurotrophic factor (CNTF): New facets of an old molecule for treating neurodegenerative and metabolic syndrome pathologies</article-title>
<source/>Cytokine Growth Factor Rev
          <year>2015</year>
<volume>26</volume>
<issue>5</issue>
<fpage>507</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.07.007</pub-id>
<pub-id pub-id-type="pmid">26187860</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>ZY</given-names>
</name>
</person-group>
<article-title>Development of neurotrophic molecules for treatment of neurodegeneration</article-title>
<source/>Curr Protein Pept Sci
          <year>2001</year>
<volume>2</volume>
<fpage>261</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.2174/1389203013381125</pub-id>
<pub-id pub-id-type="pmid">12369936</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer’s disease mechanisms</article-title>
<source/>Curr Alzheimer Res
          <year>2007</year>
<volume>4</volume>
<fpage>503</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.2174/156720507783018316</pub-id>
<pub-id pub-id-type="pmid">18220511</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s therapeutics: neurotrophin domain small molecule mimetics</article-title>
<source/>J Mol Neurosci
          <year>2003</year>
<volume>20</volume>
<fpage>323</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1385/JMN:20:3:323</pub-id>
<pub-id pub-id-type="pmid">14501015</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>ACTSG</collab>
</person-group>
<article-title>A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group</article-title>
<source/>Neurology
          <year>1996</year>
<volume>46</volume>
<fpage>1244</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.46.5.1244</pub-id>
<pub-id pub-id-type="pmid">8628460</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Penn</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>York</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giess</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tonn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haigh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Malta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Traub</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toyka</surname>
<given-names>KV</given-names>
</name>
</person-group>
<article-title>A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis</article-title>
<source/>Amyotroph Lateral Scler Other Motor Neuron Disord
          <year>2000</year>
<volume>1</volume>
<fpage>201</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1080/14660820050515197</pub-id>
<pub-id pub-id-type="pmid">11464953</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Neurotrophin-based strategies for neuroprotection</article-title>
<source/>J Alzheimers Dis
          <year>2004</year>
<volume>6</volume>
<fpage>S13</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15665408</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Neurotrophin receptor-based strategies for Alzheimer’s disease</article-title>
<source/>Curr Alzheimer Res
          <year>2005</year>
<volume>2</volume>
<fpage>167</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.2174/1567205053585819</pub-id>
<pub-id pub-id-type="pmid">15974914</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease</article-title>
<source/>Nat Rev Drug Discov
          <year>2013</year>
<volume>12</volume>
<fpage>507</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1038/nrd4024</pub-id>
<pub-id pub-id-type="pmid">23977697</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s therapeutics: neurotrophin small molecule mimetics</article-title>
<source/>J Mol Neurosci
          <year>2002</year>
<volume>19</volume>
<fpage>107</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-002-0019-1</pub-id>
<pub-id pub-id-type="pmid">12212765</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Neurotrophin small-molecule mimetics</article-title>
<source/>Prog Brain Res
          <year>2000</year>
<volume>128</volume>
<fpage>333</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/S0079-6123(00)28030-8</pub-id>
<pub-id pub-id-type="pmid">11105692</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Manthorpe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Varon</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor-dependent mechanism</article-title>
<source/>J Neurosci Res
          <year>1997</year>
<volume>48</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19970401)48:1&lt;1::AID-JNR1&gt;3.0.CO;2-K</pub-id>
<pub-id pub-id-type="pmid">9086177</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Panova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Eisenhauer</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Blusztajn</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lopez-Coviella</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gilchrest</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>A cyclic peptide that binds p75(NTR) protects neurones from beta amyloid (1–40)-induced cell death</article-title>
<source/>Neuropathol Appl Neurobiol
          <year>2007</year>
<volume>33</volume>
<fpage>533</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">17596181</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruno</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Seltzer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quirion</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cuello</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Saragovi</surname>
<given-names>HU</given-names>
</name>
</person-group>
<article-title>Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA</article-title>
<source/>J Neurosci
          <year>2004</year>
<volume>24</volume>
<fpage>8009</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1508-04.2004</pub-id>
<pub-id pub-id-type="pmid">15371501</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aboulkassim</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>XK</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Neet</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Brahimi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saragovi</surname>
<given-names>HU</given-names>
</name>
</person-group>
<article-title>Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory</article-title>
<source/>Mol Pharmacol
          <year>2011</year>
<volume>80</volume>
<fpage>498</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="doi">10.1124/mol.111.071332</pub-id>
<pub-id pub-id-type="pmid">21616921</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>McClintock</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Small molecules activating TrkB receptor for treating a variety of CNS disorders</article-title>
<source/>CNS Neurol Disord Drug Targets
          <year>2013</year>
<volume>12</volume>
<fpage>1066</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.2174/18715273113129990089</pub-id>
<pub-id pub-id-type="pmid">23844685</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yepes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Blanchi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>2687</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0913572107</pub-id>
<pub-id pub-id-type="pmid">20133810</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Obianyo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Biochemical and biophysical investigation of the brain-derived neurotrophic factor mimetic 7,8-dihydroxyflavone in the binding and activation of the TrkB receptor</article-title>
<source/>J Biol Chem
          <year>2014</year>
<volume>289</volume>
<fpage>27571</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M114.562561</pub-id>
<pub-id pub-id-type="pmid">25143381</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castello</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>7,8-Dihydroxyflavone, a small molecule TrkB agonist, improves spatial memory and increases thin spine density in a mouse model of Alzheimer disease-like neuronal loss</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e91453</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0091453</pub-id>
<pub-id pub-id-type="pmid">24614170</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction</article-title>
<source/>Rejuvenation Res
          <year>2014</year>
<volume>17</volume>
<fpage>249</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1089/rej.2013.1519</pub-id>
<pub-id pub-id-type="pmid">24325271</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Weinshenker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<fpage>638</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2013.243</pub-id>
<pub-id pub-id-type="pmid">24022672</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders</article-title>
<source/>Transl Neurodegeneration
          <year>2016</year>
<volume>5</volume>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/s40035-015-0048-7</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bilgen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joyce</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Nehama</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rajadas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents</article-title>
<source/>J Clin Invest
          <year>2010</year>
<volume>120</volume>
<fpage>1774</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1172/JCI41356</pub-id>
<pub-id pub-id-type="pmid">20407211</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>France</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sayeed</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Andero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deoxygedunin, a natural product with potent neurotrophic activity in mice</article-title>
<source/>PLoS One
          <year>2010</year>
<volume>5</volume>
<fpage>e11528</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0011528</pub-id>
<pub-id pub-id-type="pmid">20644624</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pradoldej</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tosini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Iuvone</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>N-acetylserotonin activates TrkB receptor in a circadian rhythm</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>3876</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0912531107</pub-id>
<pub-id pub-id-type="pmid">20133677</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Activation of Trk neurotrophin receptors in the absence of neurotrophins</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2001</year>
<volume>98</volume>
<fpage>3555</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.061020198</pub-id>
<pub-id pub-id-type="pmid">11248116</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>9096</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M107421200</pub-id>
<pub-id pub-id-type="pmid">11784714</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fletcher</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor</article-title>
<source/>J Pept Sci
          <year>2006</year>
<volume>12</volume>
<fpage>515</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="doi">10.1002/psc.760</pub-id>
<pub-id pub-id-type="pmid">16680799</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Leary</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Design of potent peptide mimetics of brain-derived neurotrophic factor</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>25738</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M303209200</pub-id>
<pub-id pub-id-type="pmid">12730196</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardenas-Aguayo Mdel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kazim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e53596</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0053596</pub-id>
<pub-id pub-id-type="pmid">23320097</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arancio</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Andreasson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rajadas</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<fpage>e3604</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0003604</pub-id>
<pub-id pub-id-type="pmid">18978948</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knowles</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Vander Griend</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arancio</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer’s mouse model</article-title>
<source/>Neurobiol Aging
          <year>2013</year>
<volume>34</volume>
<fpage>2052</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.02.015</pub-id>
<pub-id pub-id-type="pmid">23545424</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simmons</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Belichenko</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Finkle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Massa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer’s disease mouse models with mid- to late-stage disease progression</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e102136</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0102136</pub-id>
<pub-id pub-id-type="pmid">25153701</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis</article-title>
<source/>Neurobiol Aging
          <year>2007</year>
<volume>28</volume>
<fpage>1148</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.05.036</pub-id>
<pub-id pub-id-type="pmid">16859812</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Heaney</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Rabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide</article-title>
<source/>Neurobiol Aging
          <year>2011</year>
<volume>32</volume>
<fpage>1420</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.08.008</pub-id>
<pub-id pub-id-type="pmid">19767127</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Basurto-Islas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Kohlbrenner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide</article-title>
<source/>Acta Neuropathol
          <year>2012</year>
<volume>123</volume>
<fpage>133</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-011-0908-x</pub-id>
<pub-id pub-id-type="pmid">22083255</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oddo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caccamo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Golde</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Kayed</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Metherate</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Akbari</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction</article-title>
<source/>Neuron
          <year>2003</year>
<volume>39</volume>
<fpage>409</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(03)00434-3</pub-id>
<pub-id pub-id-type="pmid">12895417</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billings</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Oddo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>McGaugh</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice</article-title>
<source/>Neuron
          <year>2005</year>
<volume>45</volume>
<fpage>675</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2005.01.040</pub-id>
<pub-id pub-id-type="pmid">15748844</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Eacott</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Easton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gigg</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Episodic-like memory is sensitive to both Alzheimer’s-like pathological accumulation and normal ageing processes in mice</article-title>
<source/>Behav Brain Res
          <year>2013</year>
<volume>254</volume>
<fpage>73</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2013.03.009</pub-id>
<pub-id pub-id-type="pmid">23500896</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Reference and working memory deficits in the 3xTg-AD mouse between 2 and 15-months of age: A cross-sectional study</article-title>
<source/>Behav Brain Res
          <year>2015</year>
<volume>278</volume>
<fpage>496</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2014.10.033</pub-id>
<pub-id pub-id-type="pmid">25446812</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rockenstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ubhi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doppler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moessler</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mante</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AbetaPP transgenic mice</article-title>
<source/>J Alzheimers Dis
          <year>2011</year>
<volume>27</volume>
<fpage>743</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">21860085</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bolognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Rabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2011</year>
<volume>70</volume>
<fpage>1070</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1097/NEN.0b013e318236e9ad</pub-id>
<pub-id pub-id-type="pmid">22082658</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Cardenas-Aguayo Mdel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Arif</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fayyaz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Sera from children with autism induce autistic features which can be rescued with a CNTF small peptide mimetic in rats</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0118627</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0118627</pub-id>
<pub-id pub-id-type="pmid">25769033</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Bragina</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kazim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Statom</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baazaoui</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bragin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nemoto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yonas</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury</article-title>
<source/>Neurosurg
          <year>2015</year>
<volume>76</volume>
<fpage>201</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1227/NEU.0000000000000577</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice</article-title>
<source/>J Alzheimers Dis
          <year>2010</year>
<volume>21</volume>
<fpage>1185</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">20952820</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wanka</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chohan</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice</article-title>
<source/>FEBS Lett
          <year>2010</year>
<volume>584</volume>
<fpage>3359</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2010.06.025</pub-id>
<pub-id pub-id-type="pmid">20600002</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buffelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puolivali</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound</article-title>
<source/>Neurobiol Aging
          <year>2014</year>
<volume>35</volume>
<fpage>2134</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.02.017</pub-id>
<pub-id pub-id-type="pmid">24702821</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khatoon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chalbot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bolognin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Puolivali</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Elevated tau level in aged rat cerebrospinal fluid reduced by treatment with a neurotrophic compound</article-title>
<source/>J Alzheimers Dis
          <year>2015</year>
<volume>47</volume>
<fpage>557</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-142799</pub-id>
<pub-id pub-id-type="pmid">26401692</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Atlas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ginzburg</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism</article-title>
<source/>Eur J Neurosci
          <year>2005</year>
<volume>22</volume>
<fpage>1081</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04290.x</pub-id>
<pub-id pub-id-type="pmid">16176349</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DaRocha-Souto</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Coma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perez-Nievas</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Scotton</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Siao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez-Ferrer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hudry</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barroeta</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer’s disease</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>45</volume>
<fpage>425</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.09.002</pub-id>
<pub-id pub-id-type="pmid">21945540</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sereno</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Coma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez-Ferrer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Gich</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Agullo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guardia-Laguarta</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo</article-title>
<source/>Neurobiol Dis
          <year>2009</year>
<volume>35</volume>
<fpage>359</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2009.05.025</pub-id>
<pub-id pub-id-type="pmid">19523516</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>